SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies Article Swipe

PDF

Courtney D. DiNardo , Amir T. Fathi , Ashwin Kishtagari , Kapil N. Bhalla , Alfonso Quintás-Cardama , Sarah A. Reilly , Caroline Almon , Caitlin Patriquin , Salah Nabhan , Kathleen Healy , Denice Hickman , Michael P. Collins , Alexis Khalil , Dillon Corrigan , Tina Zhao , Jessica Piel , Kelly Lyons , Kim Horrigan , Virna Schuck , Paul Martin , GiNell Elliott , David L. Lahr , Mia Bosinger , Katie D’Aco , Gromoslaw A. Smolen , Martin Hentemann , Sanam Loghavi , Samuel Agresta , Michael R. Savona , Eytan M. Stein ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.29313416

Supplementary Figure 1. Flow of patients through Study FHD-286-C-002 (monotherapy dose escalation).

Related Topics

Concepts

SMARCA4 Dual (grammatical number) Medicine Myeloid Cancer research Biology Epigenetics Genetics Gene Philosophy Linguistics Chromatin remodeling

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.29313416
PDF: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4411283977

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4411283977

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.29313416

Digital Object Identifier
Title: Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-06-13

Full publication date if available
Authors: Courtney D. DiNardo, Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás-Cardama, Sarah A. Reilly, Caroline Almon, Caitlin Patriquin, Salah Nabhan, Kathleen Healy, Denice Hickman, Michael P. Collins, Alexis Khalil, Dillon Corrigan, Tina Zhao, Jessica Piel, Kelly Lyons, Kim Horrigan, Virna Schuck, Paul Martin, GiNell Elliott, David L. Lahr, Mia Bosinger, Katie D’Aco, Gromoslaw A. Smolen, Martin Hentemann, Sanam Loghavi, Samuel Agresta, Michael R. Savona, Eytan M. Stein

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.29313416

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf

Direct OA link when available
Concepts: SMARCA4, Dual (grammatical number), Medicine, Myeloid, Cancer research, Biology, Epigenetics, Genetics, Gene, Philosophy, Linguistics, Chromatin remodeling

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4411283977
doi	https://doi.org/10.1158/1078-0432.29313416
ids.doi	https://doi.org/10.1158/1078-0432.29313416
ids.openalex	https://openalex.org/W4411283977
fwci	0.0
type	preprint
title	Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T12820
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9969000220298767
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1312
topics[0].subfield.display_name	Molecular Biology
topics[0].display_name	Chromatin Remodeling and Cancer
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C80828422
concepts[0].level	5
concepts[0].score	0.7819643020629883
concepts[0].wikidata	https://www.wikidata.org/wiki/Q18031595
concepts[0].display_name	SMARCA4
concepts[1].id	https://openalex.org/C2780980858
concepts[1].level	2
concepts[1].score	0.537690281867981
concepts[1].wikidata	https://www.wikidata.org/wiki/Q110022
concepts[1].display_name	Dual (grammatical number)
concepts[2].id	https://openalex.org/C71924100
concepts[2].level	0
concepts[2].score	0.5255495309829712
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[2].display_name	Medicine
concepts[3].id	https://openalex.org/C2779282312
concepts[3].level	2
concepts[3].score	0.5081806182861328
concepts[3].wikidata	https://www.wikidata.org/wiki/Q1956561
concepts[3].display_name	Myeloid
concepts[4].id	https://openalex.org/C502942594
concepts[4].level	1
concepts[4].score	0.49380192160606384
concepts[4].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[4].display_name	Cancer research
concepts[5].id	https://openalex.org/C86803240
concepts[5].level	0
concepts[5].score	0.19178006052970886
concepts[5].wikidata	https://www.wikidata.org/wiki/Q420
concepts[5].display_name	Biology
concepts[6].id	https://openalex.org/C41091548
concepts[6].level	3
concepts[6].score	0.12786865234375
concepts[6].wikidata	https://www.wikidata.org/wiki/Q26939
concepts[6].display_name	Epigenetics
concepts[7].id	https://openalex.org/C54355233
concepts[7].level	1
concepts[7].score	0.11469867825508118
concepts[7].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[7].display_name	Genetics
concepts[8].id	https://openalex.org/C104317684
concepts[8].level	2
concepts[8].score	0.07588714361190796
concepts[8].wikidata	https://www.wikidata.org/wiki/Q7187
concepts[8].display_name	Gene
concepts[9].id	https://openalex.org/C138885662
concepts[9].level	0
concepts[9].score	0.05657219886779785
concepts[9].wikidata	https://www.wikidata.org/wiki/Q5891
concepts[9].display_name	Philosophy
concepts[10].id	https://openalex.org/C41895202
concepts[10].level	1
concepts[10].score	0.0
concepts[10].wikidata	https://www.wikidata.org/wiki/Q8162
concepts[10].display_name	Linguistics
concepts[11].id	https://openalex.org/C167227067
concepts[11].level	4
concepts[11].score	0.0
concepts[11].wikidata	https://www.wikidata.org/wiki/Q5113739
concepts[11].display_name	Chromatin remodeling
keywords[0].id	https://openalex.org/keywords/smarca4
keywords[0].score	0.7819643020629883
keywords[0].display_name	SMARCA4
keywords[1].id	https://openalex.org/keywords/dual
keywords[1].score	0.537690281867981
keywords[1].display_name	Dual (grammatical number)
keywords[2].id	https://openalex.org/keywords/medicine
keywords[2].score	0.5255495309829712
keywords[2].display_name	Medicine
keywords[3].id	https://openalex.org/keywords/myeloid
keywords[3].score	0.5081806182861328
keywords[3].display_name	Myeloid
keywords[4].id	https://openalex.org/keywords/cancer-research
keywords[4].score	0.49380192160606384
keywords[4].display_name	Cancer research
keywords[5].id	https://openalex.org/keywords/biology
keywords[5].score	0.19178006052970886
keywords[5].display_name	Biology
keywords[6].id	https://openalex.org/keywords/epigenetics
keywords[6].score	0.12786865234375
keywords[6].display_name	Epigenetics
keywords[7].id	https://openalex.org/keywords/genetics
keywords[7].score	0.11469867825508118
keywords[7].display_name	Genetics
keywords[8].id	https://openalex.org/keywords/gene
keywords[8].score	0.07588714361190796
keywords[8].display_name	Gene
keywords[9].id	https://openalex.org/keywords/philosophy
keywords[9].score	0.05657219886779785
keywords[9].display_name	Philosophy
language	en
locations[0].id	doi:10.1158/1078-0432.29313416
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.29313416
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5010786159
authorships[0].author.orcid	https://orcid.org/0000-0001-9003-0390
authorships[0].author.display_name	Courtney D. DiNardo
authorships[0].author_position	first
authorships[0].raw_author_name	Courtney D. DiNardo
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5081916808
authorships[1].author.orcid	https://orcid.org/0000-0002-5848-6221
authorships[1].author.display_name	Amir T. Fathi
authorships[1].author_position	middle
authorships[1].raw_author_name	Amir T. Fathi
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5061478349
authorships[2].author.orcid	https://orcid.org/0000-0003-1149-4571
authorships[2].author.display_name	Ashwin Kishtagari
authorships[2].author_position	middle
authorships[2].raw_author_name	Ashwin Kishtagari
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5079069209
authorships[3].author.orcid	https://orcid.org/0000-0001-5209-5126
authorships[3].author.display_name	Kapil N. Bhalla
authorships[3].author_position	middle
authorships[3].raw_author_name	Kapil N. Bhalla
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5107977581
authorships[4].author.orcid	https://orcid.org/0000-0002-4623-8917
authorships[4].author.display_name	Alfonso Quintás-Cardama
authorships[4].author_position	middle
authorships[4].raw_author_name	Alfonso Quintás-Cardama
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5113042998
authorships[5].author.orcid
authorships[5].author.display_name	Sarah A. Reilly
authorships[5].author_position	middle
authorships[5].raw_author_name	Sarah A. Reilly
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5023808130
authorships[6].author.orcid
authorships[6].author.display_name	Caroline Almon
authorships[6].author_position	middle
authorships[6].raw_author_name	Caroline Almon
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5037341109
authorships[7].author.orcid
authorships[7].author.display_name	Caitlin Patriquin
authorships[7].author_position	middle
authorships[7].raw_author_name	Caitlin Patriquin
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5082846098
authorships[8].author.orcid
authorships[8].author.display_name	Salah Nabhan
authorships[8].author_position	middle
authorships[8].raw_author_name	Salah Nabhan
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5112002821
authorships[9].author.orcid
authorships[9].author.display_name	Kathleen Healy
authorships[9].author_position	middle
authorships[9].raw_author_name	Kathleen Healy
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5110610157
authorships[10].author.orcid
authorships[10].author.display_name	Denice Hickman
authorships[10].author_position	middle
authorships[10].raw_author_name	Denice Hickman
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5009275057
authorships[11].author.orcid	https://orcid.org/0000-0002-1806-6775
authorships[11].author.display_name	Michael P. Collins
authorships[11].author_position	middle
authorships[11].raw_author_name	Michael P. Collins
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5109477793
authorships[12].author.orcid	https://orcid.org/0009-0008-9231-7641
authorships[12].author.display_name	Alexis Khalil
authorships[12].author_position	middle
authorships[12].raw_author_name	Alexis Khalil
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5011741920
authorships[13].author.orcid	https://orcid.org/0000-0002-5390-0139
authorships[13].author.display_name	Dillon Corrigan
authorships[13].author_position	middle
authorships[13].raw_author_name	Dillon Corrigan
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5111072886
authorships[14].author.orcid
authorships[14].author.display_name	Tina Zhao
authorships[14].author_position	middle
authorships[14].raw_author_name	Tina Zhao
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5084422325
authorships[15].author.orcid
authorships[15].author.display_name	Jessica Piel
authorships[15].author_position	middle
authorships[15].raw_author_name	Jessica Piel
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5117174556
authorships[16].author.orcid
authorships[16].author.display_name	Kelly Lyons
authorships[16].author_position	middle
authorships[16].raw_author_name	Kelly Lyons
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5001848151
authorships[17].author.orcid
authorships[17].author.display_name	Kim Horrigan
authorships[17].author_position	middle
authorships[17].raw_author_name	Kim Horrigan
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5079072028
authorships[18].author.orcid
authorships[18].author.display_name	Virna Schuck
authorships[18].author_position	middle
authorships[18].raw_author_name	Virna Schuck
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5102851619
authorships[19].author.orcid	https://orcid.org/0009-0002-2598-4520
authorships[19].author.display_name	Paul Martin
authorships[19].author_position	middle
authorships[19].raw_author_name	Paul Martin
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5018852765
authorships[20].author.orcid
authorships[20].author.display_name	GiNell Elliott
authorships[20].author_position	middle
authorships[20].raw_author_name	GiNell Elliott
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5078970169
authorships[21].author.orcid	https://orcid.org/0000-0001-6283-0286
authorships[21].author.display_name	David L. Lahr
authorships[21].author_position	middle
authorships[21].raw_author_name	David L. Lahr
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5117174557
authorships[22].author.orcid
authorships[22].author.display_name	Mia Bosinger
authorships[22].author_position	middle
authorships[22].raw_author_name	Mia Bosinger
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5061704560
authorships[23].author.orcid	https://orcid.org/0000-0003-3215-7697
authorships[23].author.display_name	Katie D’Aco
authorships[23].author_position	middle
authorships[23].raw_author_name	Katie D’Aco
authorships[23].is_corresponding	False
authorships[24].author.id	https://openalex.org/A5019396643
authorships[24].author.orcid	https://orcid.org/0000-0003-0136-4685
authorships[24].author.display_name	Gromoslaw A. Smolen
authorships[24].author_position	middle
authorships[24].raw_author_name	Gromoslaw Aleksander Smolen
authorships[24].is_corresponding	False
authorships[25].author.id	https://openalex.org/A5047249666
authorships[25].author.orcid
authorships[25].author.display_name	Martin Hentemann
authorships[25].author_position	middle
authorships[25].raw_author_name	Martin Hentemann
authorships[25].is_corresponding	False
authorships[26].author.id	https://openalex.org/A5056317446
authorships[26].author.orcid	https://orcid.org/0000-0001-8980-3202
authorships[26].author.display_name	Sanam Loghavi
authorships[26].author_position	middle
authorships[26].raw_author_name	Sanam Loghavi
authorships[26].is_corresponding	False
authorships[27].author.id	https://openalex.org/A5108267512
authorships[27].author.orcid
authorships[27].author.display_name	Samuel Agresta
authorships[27].author_position	middle
authorships[27].raw_author_name	Samuel Agresta
authorships[27].is_corresponding	False
authorships[28].author.id	https://openalex.org/A5049400849
authorships[28].author.orcid	https://orcid.org/0000-0003-3763-5504
authorships[28].author.display_name	Michael R. Savona
authorships[28].author_position	middle
authorships[28].raw_author_name	Michael R. Savona
authorships[28].is_corresponding	False
authorships[29].author.id	https://openalex.org/A5066934816
authorships[29].author.orcid	https://orcid.org/0000-0001-8992-9390
authorships[29].author.display_name	Eytan M. Stein
authorships[29].author_position	last
authorships[29].raw_author_name	Eytan M. Stein
authorships[29].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T12820
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9969000220298767
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1312
primary_topic.subfield.display_name	Molecular Biology
primary_topic.display_name	Chromatin Remodeling and Cancer
related_works	https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W4388045456, https://openalex.org/W1506200166
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.29313416
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.29313416
primary_location.id	doi:10.1158/1078-0432.29313416
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_A_Phase_I_Study_of_FHD-286_a_Dual_BRG1_BRM_SMARCA4_SMARCA2_Inhibitor_in_Patients_with_Advanced_Myeloid_Malignancies/29313416/1/files/55361255.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.29313416
publication_date	2025-06-13
publication_year	2025
referenced_works_count	0
abstract_inverted_index.1.	2
abstract_inverted_index.of	4
abstract_inverted_index.Flow	3
abstract_inverted_index.dose	10
abstract_inverted_index.Study	7
abstract_inverted_index.Figure	1
abstract_inverted_index.through	6
abstract_inverted_index.patients	5
abstract_inverted_index.(monotherapy	9
abstract_inverted_index.FHD-286-C-002	8
abstract_inverted_index.<p>Supplementary	0
abstract_inverted_index.escalation).</p>	11
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	30
citation_normalized_percentile.value	0.21549421
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False